Biosplice Therapeutics Stock
Tissue-Level Regeneration
Sign up today and learn more about Biosplice Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Biosplice Therapeutics Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
Starling group
Vickers Venture Partners
Polar Light Ventures
Esas Ventures
Sands Capital Management
Funding History
February 2021 | $60.0M |
---|---|
March 2021 | $60.0M |
Management
Chief Executive Officer
Samikoglu Cevdet
Chief Financial Officer
Horsley Erich
Press
patents - Apr, 15 2024
1h-pyrrolo[2,3-b]pyridines as dyrk1a inhibitorspatents - Apr, 15 2024
4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereofpatents - Apr, 15 2024
7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOFpatents - Apr, 15 2024
Isoquinolin-3-yl carboxamides and preparation and use thereofpatents - Apr, 15 2024
Gamma-diketones for treatment and prevention of aging skin and wrinkles